Shares of the biopharmaceutical company rose after it released more mature overall survival data from its Phase III HARMONi trial for ivonescimab, its treatment for a specific type of non-small cell lung cancer, ahead of a key FDA decision.
Shares of the Swiss pharmaceutical manufacturer fell after Berenberg began coverage with a 'Hold' rating and a CHF 77 price target, citing limited visibility on project execution and a pending contract weighing on 2026 growth.
The biopharmaceutical company announced that its drug plozasiran met primary and secondary endpoints in two late-stage trials for severe hypertriglyceridemia, prompting a significant stock rally.
Shares of generic drugmaker Sandoz dropped nearly 3% following a proposal by U.S. President Donald Trump to impose steep future tariffs on imported medicines, clouding the outlook for the company's significant U.S. business.
An analysis by Investing.com's AI-driven tool suggests animal health firm Zoetis (ZTS) is trading at a significant discount, with a potential upside of over 61% as its stock hovers near 52-week lows.
The U.S. Army is making significant progress toward the Pentagon's first-ever clean financial audit by 2028, with new consolidated systems revealing critical data errors in equipment and property records.
UBS analysts upgraded hearing aid manufacturer Sonova to 'buy' from 'neutral,' citing an attractive valuation discount to a key rival and an underappreciated product pipeline, sending the company's shares up more than 5%.
Shares of the AI server maker jumped in pre-market trading after its preliminary Q4 results revealed a significant gross margin beat and a $60 billion order backlog, though analysts remain cautious amid ongoing governance concerns.
JPMorgan has upgraded Epiroc to Overweight and downgraded Sandvik to Neutral, citing Epiroc's superior exposure to the copper market and growing risks from tungsten prices for Sandvik.
